{"id":920897,"date":"2025-12-18T09:25:29","date_gmt":"2025-12-18T14:25:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/"},"modified":"2025-12-18T09:25:29","modified_gmt":"2025-12-18T14:25:29","slug":"salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/","title":{"rendered":"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker \u201cDCOY\u201d effective in early January 2026<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value<\/em>\n      <\/p>\n<p>HOUSTON, Dec.  18, 2025  (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY.<\/p>\n<p>The planned name and ticker change mark a pivotal step in the Company\u2019s transformation into a platform-driven biotechnology company focused on novel peptide-conjugate therapeutics with applications across viral diseases and oncology.<\/p>\n<p>The Company expects the name and ticker symbol change to become effective in early January 2026. The Company will continue to trade under the existing symbol SLRX until the effective date. The Company&#8217;s transfer agent will remain unchanged. Stockholder approval was not required to take any specific action with respect to the corporate name change or new ticker symbol. The corporate name change and new ticker symbol will not impact the Company&#8217;s operations. As previously announced Decoy\u2019s senior management team joined by Salarius\u2019s finance team will lead the new Company\u2019s operations.<\/p>\n<p>\u201cThis planned rebrand reflects far more than a name change, it represents the strategic foundation of the combined companies,\u201d said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. \u201cWith the merger complete, we are now singularly focused on advancing integration of Decoy\u2019s differentiated therapeutic platforms, expanding our pipeline and creating multiple value-inflection opportunities through data generation, program advancements, including getting our lead program into human clinical trials.\u201d<\/p>\n<p>\n        <strong>A Platform Built for Scale, Speed, and Strategic Partnerships<\/strong><br \/>\n        <br \/>Decoy Therapeutics is advancing a proprietary peptide-conjugate platform designed to selectively intercept and neutralize high-value biological targets, with early programs addressing pan-coronavirus activity and multi-viral threats, including influenza and RSV. The Company\u2019s lead antiviral program has attracted strategic interest from the Biomedical Advanced Research and Development Authority (BARDA) and global health organizations, positioning Decoy to pursue additional non-dilutive grant funding, collaborations, and future development partnerships as data emerge.<\/p>\n<p>In parallel, Decoy is advancing next-generation discovery programs, including:<\/p>\n<ul type=\"disc\">\n<li>Multi-virus decoy candidates designed to address overlapping respiratory threats<\/li>\n<li>Cell-based and organoid-level validation of novel GPCR targeted drug candidates outside of antivirals<\/li>\n<\/ul>\n<p>Together, these efforts are intended to support multiple investigational new drug (IND) applications and their enabling activities, peer-reviewed publications, and partnering discussions, while maintaining capital efficiency and flexibility.<\/p>\n<p>\n        <strong>2026 Focus: Execution, Data and Potential Milestones<\/strong>\n      <\/p>\n<p>Looking ahead, the Company plans to prioritize:<\/p>\n<ul type=\"disc\">\n<li>Advancing lead antiviral programs toward regulatory readiness<\/li>\n<li>Expanding discovery and preclinical validation across multiple platforms<\/li>\n<li>Leveraging AI-enabled computational infrastructure to accelerate candidate selection<\/li>\n<li>Pursuing strategic collaborations with big pharma, technology leaders, and academic institutions<\/li>\n<li>Strengthening the Company\u2019s capital structure and investor visibility\n<\/li>\n<\/ul>\n<p>The Company believes this execution-focused approach positions Decoy Therapeutics to generate multiple shots on goal while retaining upside through partnerships and non-dilutive funding sources.<\/p>\n<p>\n        <strong>About Decoy Therapeutics Inc.<\/strong><br \/>\n        <br \/>Salarius\u2019 subsidiary Decoy is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company\u2019s initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the BARDA through BLUE KNIGHT\u2122, a collaboration between Johnson &amp; Johnson Innovation \u2013 JLABS and BARDA within the Administration for Strategic Preparedness and Response.<\/p>\n<p>\n        <strong>About Salarius Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p>Salarius is a clinical-stage biopharmaceutical company with two drug candidates for patients with cancer in need of new treatment options. Salarius\u2019 product portfolio includes seclidemstat, the company\u2019s lead candidate, which is being studied in an investigator-initiated Phase 1\/2 clinical study in hematologic cancers underway at MD Anderson Cancer Center as a potential treatment for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options. SP-3164, the company\u2019s IND-stage second asset, is an oral small molecule protein degrader. Salarius previously received financial support for seclidemstat for the treatment of Ewing sarcoma from the\u00a0National Pediatric Cancer Foundation and was a recipient of a Product Development Award from the\u00a0Cancer Prevention and Research Institute of Texas. For more information, please visit www.salariuspharma.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the Company, including expected achievement of milestones for its lead asset and future prospects of the Company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of the Company, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cmay,\u201d \u201cwill,\u201d \u201ccan,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201clikely,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy\u2019s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT\u2122 platform. Readers are urged to carefully review and consider the various disclosures made by Salarius in its reports filed with the SEC, including its Current Report on Form 8-K filed with the SEC on August 22, 2025, its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, the Company\u2019s actual results may vary materially from those expected or projected.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>\n        <strong>Salarius Pharmaceuticals<\/strong><br \/>\n        <br \/>Rick Pierce, CEO<br \/>Pierce@decoytx.com<br \/>617-447-8299<\/p>\n<p>\n        <strong>Business Development<\/strong><br \/>\n        <br \/>Peter Marschel, CBO<br \/>Peter@Decoytx.com<br \/>617-943-6305<\/p>\n<p>\n        <strong>Investors and Media<\/strong><br \/>\n        <br \/>Alliance Advisors IR<br \/>Jody Cain<br \/>jcain@allianceadvisors.com<br \/>310-691-7100<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(908) 824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4Zk8tcntMnpgg47koD10X8pioo8k3SwNXAcQz1u7HkKRwwBiiDI8KtaZANh8xkmKv6fcjHZHz8YQRHpXh5qm_Q==\" rel=\"nofollow\" target=\"_blank\">dcoy@jtcir.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWI3ODY0ZmYtZTViZS00N2RhLWI5MjYtMTdkOWUwNjgzOTAzLTEwMjgzNTAtMjAyNS0xMi0xOC1lbg==\/tiny\/Salarius-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker \u201cDCOY\u201d effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY. The planned name and ticker change mark a pivotal step in the Company\u2019s transformation into a platform-driven biotechnology &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-920897","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker \u201cDCOY\u201d effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY. The planned name and ticker change mark a pivotal step in the Company\u2019s transformation into a platform-driven biotechnology &hellip; Continue reading &quot;Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-18T14:25:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform\",\"datePublished\":\"2025-12-18T14:25:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/\"},\"wordCount\":1132,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/\",\"name\":\"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=\",\"datePublished\":\"2025-12-18T14:25:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - Market Newsdesk","og_description":"The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker \u201cDCOY\u201d effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY. The planned name and ticker change mark a pivotal step in the Company\u2019s transformation into a platform-driven biotechnology &hellip; Continue reading \"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-18T14:25:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform","datePublished":"2025-12-18T14:25:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/"},"wordCount":1132,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/","name":"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=","datePublished":"2025-12-18T14:25:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYwNDI3OSM3MzI3ODY5IzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-planned-corporate-name-and-ticker-symbol-change-to-decoy-therapeutics-reflecting-strategic-pivot-to-next-generation-antiviral-and-peptide-conjugate-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=920897"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920897\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=920897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=920897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=920897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}